The Neurotensin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat amygdala using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200-1/400 in PBS/0.3% Triton x-100 - Cy3 Technique and 1/4000-1/8000 in PBS/0.3% Triton x-100 - Bn/Av-HRP Technique. Staining is completely eliminated by pretreatment with 10 µg of Neurotensin per 1 mL of diluted antibody.
The ACTH Antibody was raised to ACTH (1-39) purified from porcine pituitary. The antibody produces a maximum fluorescein staining at a 1/100 - 1/200 dilution and a 4+ biotin-streptavidin/HRP staining at a 1/500 - 1/1000 dilution in rat anterior/intermediate pituitary. Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. The recommened dilution series are 1/100-1/200 in PBS/0.3% Triton X-100 - FITC Technique and 1/500-1/1000 in PBS/0.3% Triton X-100 - Bn-SA/HRP Technique. Staining is completely eliminated by pretreatment of the diluted antibody with 100 µg/mL of ACTH.
The antibody has a proven strong fluorescent staining at a 1/400 - 1/800 dilution and a proven strong biotin-streptavidin/HRP staining at a 1/2000 - 1/4000 dilution in rat hypothalamus. Staining is completely eliminated by pretreatment of the diluted antibody with 10 µg/mL of arginine vasopressin. Pre-adsorption with as much as 100 µg/mL of oxytocin had no effect on immunolabeling.
The Oxytocin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat hypothalamus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/200 - 1/400 in PBS/0.3% Triton X-100 - FITC and 1/4,000 - 1/8,000 in PBS/0.3% Triton X-100 - Bn/Av-HRP. Staining is completely eliminated by pretreatment of 1 mL of the diluted antibody with 5 µg of Oxytocin. Pretreatment of 1 mL of the diluted antibody with as much as 100 µg of vasopressin does not diminish staining.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400-1/800 dilution and strong Biotin-Streptavidin/HRP staining at a 1/1000-1/2000 dilution in rat hypothalamus (median eminence). The specificity of the antiserum was examined by soluble pre-adsorption with the peptides in question at a final concentration of 106M. Somatostatin immunolabeling was completely abolished by pre-adsorption with somatostatin, somatostatin 25, and somatostatin 28. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: substance P, amylin, glucagon, insulin, neuropeptide Y, and VIP.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400 - 1/600 dilution and a proven strong biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat globus pallidus and spinal cord. Staining is completely eliminated by pretreatment with 50 µg of Leucine Enkephalin per mL of diluted antiserum. Pretreatment with 50 µg of Methionine Enkephalin per mL of diluted antiserum also significantly blocks staining.
The antibody has a proven strong indirect immunofluorescent staining at a 1/400-1/600 dilution and a proven 4+ biotin-streptavidin/HRP staining at 1/1,000-1/1,200 dilution in rat globus pallidus and amygdala. Staining is completely eliminated by pretreatment with 100 µg of methionine enkephalin per mL of diluted antiserum. Pretreatment with 100 µg of leucine enkephalin only partially blocks staining.
The Substance P antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat substantia nigra and spinal cord using biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500-1/1000 in PBS/0.3% Triton X-100 - Cy3 Fluorchrome and 1/6000-1/8000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. The specificity of the antiserum for Substance P was demonstrated using soluble pre-adsorption with the peptides in question at a final concentration of 10 µg of peptide per mL of diluted antiserum. Substance P immunolabeling was completely abolished by pre-adsorption with Substance P. Pre-adsorption with the following peptides resulted in no reduction of immunostaining: neurokinin A, neurokinin B, somatostatin and neuropeptide K.
The Beta-Endorphin Antibody was raised to synthetic human beta endorphin coupled to KLH with carbodiimide. The antibody produces a strong indirect immunofluorescent staining at a 1/200 - 1/400 dilution and a 4+ biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat anterior pituitary. Staining is completely eliminated by pretreatment of the diluted antibody with 10-6 M of Ã-Endorphin. Pre-adsorption of the diluted antibody with 10-6M of the following substances had no effect on -Endorphin labeling: methionine enkephalin, leucine enkaphalin, dynorphin A, dynorphin B, gamma-endorphin, alpha-endorphin, ACTH and alpha-melanocyte stimulating hormone.
The histochemical antibody for Neurokinin 3 Receptor is generated in a rabbit from a synthetic peptide corresponding to rat NK3R 438-452 coupled to carrier protein. The antiserum is provided as l00 µL of affinity purified liquid.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Liquid
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat, human, mouse, dog and gerbil
Immunogen:
Synthetic peptide corresponding to rat NK3R 438-452 coupled to carrier protein.
The NK3R antiserum was quality control tested using standard immunohistochemical methods in rat hypothalamus using biotin/avidin-HRP techniques.Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with 25 mg of rat NK3R peptide residues 438-452. Western blot analysis of crude rat brain homogenate demonstrates two immunoreactive bands of approximately 80 and 115 kD.
The GAT-2 antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat retina and leptomeninges using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/100-1/200 in PBS/0.3% Triton X-100Â - Cy3 Technique and 1/500 - 1/1,000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. The antiserum has been characterized as specific to GAT-2; please see references listed below. GAT-2 immunolabeling is completely abolished by soluble pre-adsorption with synthetic rat GAT-2 (594-602) at a concentration of 10-5 M.
The histochemical antibody for Neurokinin 1 Receptor is generated in a rabbit from a synthetic peptide corresponding to rat NK1R 393-407 coupled to carrier protein. The antiserum is provided as l00 µL of lyophilized whole serum.
Product Type:
Antibody - Antibodies
Antibody Type:
polyclonal
Format:
Lyophilised
Host Animal:
Rabbit
Species Reactivity:
Rat
Expected Species:
100% sequence homology with rat and gerbil, 93% with mouse, 78% with human
Immunogen:
Synthetic peptide corresponding to rat NK1R 393-407 coupled to carrier protein.
The NK1R antiserum was quality control tested using standard immunohistochemical methods in rat brain using biotin/avidin-HRP techniques. Specificity of the antiserum was demonstrated by soluble pre-adsorption and Western blot. Tissue staining is completely eliminated by pretreatment of the diluted antibody with 10 mg of rat NK1R peptide residues 393-407. Western blot analysis demonstrates two immunoreactive bands of approximately 70 and 110 kD.
The 5-HT Antibody was raised in rabbit against 5-HTP coupled to BSA with paraformaldehyde. The antibody has a proven maximum biotin-streptavidin/HRP staining at a 1/1000 - 1/2000 dilution in rat raphe nuclei. Optimal dilution will vary depending upon fixation, labeling technique and/or detection system; therefore, a dilution series is recommended. The specificity of the antiserum was evaluated using a model system of gelatin-indole plugs by a method similar to published procedures (Shipper and Tilders, 1983). Results showed that the 5-HTP antibody dose dependently stained 5-HTP but did not stain any concentration of 5-HT or 5-HIAA. The antiserum was also tested by pre-adsorption with indole/paraformaldehyde/BSA conjugates. Staining was completely blocked by pre-adsorption with 5-HTP conjugate and unaffected by 5-HIAA or 5-HT conjugate.
The Calretinin Antibody was raised to chick calretinin fusion protein. The antibody has a proven maximum biotin-avidin/HRP staining at a 1/2000 - 1/4000 dilution in rat cortex, hippocampus and hypothalamus.
The Insulin antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat pancreatic beta cells using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions for these methods are 1/500-1/1000 in PBS/0.3% Triton X-100 - Cy3 Technique and 1/3000-1/5000 in PBS/0.3% Triton X-100 - biotin/avidin-HRP Technique. Immuostaining is completely abolished by soluble pre-adsorption with bovine insulin at 10 µg per mL of diluted antiserum.
The Neuropeptide Y Y1 Receptor was quality control tested using standard immunohistochemical methods. The antiserum demonstrates strongly positive labeling of rat cortex, arcuate and hippocampus using indirect immunofluorescent and biotin/avidin-HRP techniques. Recommended primary dilutions are 1/500 - 1/1000 in PBS - Bn/Av-HRP detection.
The antibody was characterized by immunohistochemistry and Western blot. Western blot showed one immunoreactive band of 40 kD and a single high molecular weight band, presumably a precursor molecule. Preincubation of the antibody with an excess of the synthetic peptide blocked staining. Immunohistochemical staining of rat brain correlates well with Northern analysis, in situ hybridization and receptor autoradiography. BlastP database sequence homology searches confirmed that this sequence is unique to rat, mouse and human NPY Y1 receptors.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.